(Q41082128)

26 September 2017

title

Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis (English)

1 reference

26 September 2017

3

1 reference

26 September 2017

Lise L Gluud

2

0 references

Tina Vilsbøll

series ordinal

5

object named as

Tina Vilsbøll

1 reference

26 September 2017

4

Filip K Knop

1 reference

26 September 2017

Anders E Junker

1

1 reference

26 September 2017

publication date

13 April 2015

1 reference

Journal of Gastroenterology and Hepatology

26 September 2017

published in

1 reference

26 September 2017

volume

30

1 reference

26 September 2017

issue

10

1 reference

26 September 2017

page(s)

1522-1528

1 reference

Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1.

26 September 2017

cites work

1 reference

Relationship between insulin sensitivity, insulin secretion and glucose tolerance in cirrhosis.

21 January 2018

1 reference

Hepatogenous diabetes in cirrhosis is related to portal pressure and variceal hemorrhage

21 January 2018

1 reference

Oral glucose tolerance test predicts prognosis of patients with liver cirrhosis

21 January 2018

1 reference

New developments in the incretin concept

21 January 2018

1 reference

Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes

21 January 2018

1 reference

Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

21 January 2018

1 reference

Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers

21 January 2018

1 reference

Measuring the effect of a study meal on portal concentrations of glucagon-like peptide 1 (GLP-1) in non diabetic and diabetic patients with liver cirrhosis: transjugular intrahepatic portosystemic stent shunt (TIPSS) as a new method for metabolic me

21 January 2018

1 reference

Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes

21 January 2018

1 reference

Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine

21 January 2018

1 reference

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study

21 January 2018

1 reference

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp.

21 January 2018

1 reference

Transection of the oesophagus for bleeding oesophageal varices

21 January 2018

1 reference

Insulin secretory capacity and the regulation of glucagon secretion in diabetic and non-diabetic alcoholic cirrhotic patients

21 January 2018

1 reference

Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS).

21 January 2018

1 reference

Hyperglucagonaemia in cirrhosis. Relationship to hepatocellular damage.

21 January 2018

1 reference

Metabolic handling of orally administered glucose in cirrhosis

21 January 2018

1 reference

Diagnosis and classification of diabetes mellitus

21 January 2018

1 reference

Glucose metabolism and liver cirrhosis

21 January 2018

1 reference

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

21 January 2018

1 reference

Insulin resistance in chronic hepatitis B virus infection

21 January 2018

1 reference

Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity.

21 January 2018

1 reference

Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.

21 January 2018

1 reference

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

21 January 2018

1 reference

Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus.

21 January 2018

1 reference

Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance

21 January 2018

1 reference

Portal glucose infusion exerts an incretin effect associated with changes in pancreatic neural activity in conscious dogs

21 January 2018

1 reference

Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats

21 January 2018

1 reference

Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways

21 January 2018

1 reference

Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty

21 January 2018

1 reference

Pharmacokinetic variations of acetaminophen according to liver dysfunction and portal hypertension status

21 January 2018

1 reference

Gut transit is associated with gastrointestinal symptoms and gut hormone profile in patients with cirrhosis

21 January 2018

1 reference

Reduced Incretin Effect in Type 2 Diabetes

21 January 2018

1 reference

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

21 January 2018

1 reference

The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JGH.12981

1 reference

26 September 2017

1 reference